SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma inches up as its arm receives EIR for Raleigh plant

23 Sep 2022 Evaluate

Aurobindo Pharma is currently trading at Rs. 522.00, up by 1.50 points or 0.29% from its previous closing of Rs. 520.50 on the BSE.

The scrip opened at Rs. 518.05 and has touched a high and low of Rs. 529.45 and Rs. 516.60 respectively. So far 24603 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 751.45 on 04-Oct-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 539.10 and Rs. 516.60 respectively. The current market cap of the company is Rs. 30521.54 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 38.01% and 10.15% respectively.

Aurobindo Pharma’s wholly owned step-down subsidiary -- Aurolife Pharma LLC has received an establishment inspection report (EIR) for its plant situated at Raleigh, North Carolina, USA , mentioning the inspection a voluntary action initiated (VAI) from the United States Food and Drug Administration (US FDA) and with this, the USFDA pre-approval inspection and GMP inspection are concluded.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1376.80 -8.85 (-0.64%)
20-Apr-2026 10:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.25
Dr. Reddys Lab 1235.65
Cipla 1237.60
Zydus Lifesciences 940.00
Lupin 2327.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×